Podcasts about wnl

Dr. Greg Cooper and Dr. Kerry Sheets discuss how hearing aid use affects cognition and the risk of dementia in older adults with hearing impairment.  Show citations: Cribb L, Moreno-Betancur M, Pase MP, et al. Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia. Neurology. 2026;106(3):e214572. doi:10.1212/WNL.0000000000214572  Show transcript: Dr. Greg Cooper: Hi, this is Greg Cooper. I just finished interviewing Kerry Sheets for this week's Neurology Podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your paper. Dr. Kerry Sheets: The central message of our paper is that hearing aid use in adults aged 70 years or older with hearing impairment may reduce dementia risk over 7 years. Results for the impact of hearing aid use on cognitive decline were less. Dr. Greg Cooper: Well, thank you for that summary and for all of your work on this topic. Please check out this week's podcast to hear the full interview and read the full article published in Neurology: Treating Hearing Loss with Hearing Aids for the Prevention of Cognitive Decline and Dementia. 

Dr. Halley Alexander and Dr. Abel Sandmann discuss seizure rates and risk factors in patients with cerebral cavernous malformations (CCMs) during long-term follow-up without CCM intervention.  Show citation:  Sandmann ACA, Vandertop WP, White PM, Verbaan D, Coutinho JM, Al-Shahi Salman R. Seizures and Epilepsy in Patients With Untreated Cerebral Cavernous Malformations: A Prospective, Population-Based Cohort Study. Neurology. 2025;105(11):e214387. doi:10.1212/WNL.0000000000214387  Show transcript:  Dr. Halley Alexander: Hi, this is Halley Alexander with today's Neurology Minute. I'm here with Abel Sandmann from Amsterdam University Medical Center, and we just finished recording a full-length podcast about some exciting findings related to cerebral cavernous malformations and the risk of seizures and epilepsy. Abel, can you give our listeners a rundown of the most exciting findings and how it can change practice? Dr. Abel Sandmann:  In our paper, we show that patients with a cerebral cavernous malformation who have a first unprovoked seizure should be diagnosed with epilepsy and considered for anti-seizure medication, as most of them achieve long-term seizure freedom with medical therapy alone. These findings are based on a prospective population-based cohort study in which we analyze long-term follow-up and assess the rates and risk factors for: one, a first-ever epileptic seizure; two, seizure recurrence to evaluate the updated ILAE definition of epilepsy; and three, seizure freedom over two years and five years among patients with epilepsy. We found that among patients who had never experienced a seizure before, the 10-year risk of a first-ever seizure was only 6%. This supports current recommendations against prophylactic anti-seizure medication in patients who are incidentally diagnosed with a cerebral cavernous malformation. However, following a first unprovoked seizure, the 10-year risk of recurrence was 80%, which exceeds the 60% threshold defined by the ILAE. This justifies diagnosing epilepsy after the first and provoked seizure in this population. Given that the risk of recurrence was lower in patients treated with anti-seizure medication after the first seizure, this supports early initiation of therapy, although these treatment analyses were non-randomized and should be interpreted cautiously. Most patients who met the definition of epilepsy became two year and five years seizure-free with medical management alone. But some patients with cerebral cavernous malformations develop medically intractable seizures and might benefit from surgical treatments. Dr. Halley Alexander: Excellent. Thank you so much, Abel. You can find the full-length podcast, which is available now on the Neurology Podcast, or you can also find the full article in Neurology at neurology.org, or in the December 2025 print issue. As always, thanks for tuning in for today's Neurology Minute.   

Te gast zijn minister van Buitenlandse Zaken Tom Berendsen over zijn eerste weken als minister en over Iran, Ingrid Coenradie van JA21 over hoe Pim Fortuyn haar inspireerde en Wim Voermans over de gemeenteraadsverkiezingen, die niet meer zo populair zijn. Hij legt het belang uit. Café Kockelmann is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Met 11 miljoen euro boekt de NS na zware jaren voor het eerst weer winst. Met duurdere treinkaartjes en nieuw materieel gaat de NS gestaag verder. Sven met NS-baas Wouter Koolmees over de toekomst van de Nederlandse Spoorwegen. Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Het is inmiddels dag 6 van de oorlog in het Midden-Oosten, en de eenheid in Europa is ver zoek: terwijl Frankrijk het voortouw neemt en hun vliegdekschip richting de Middellandse Zee stuurt, weigert Spanje betrokken te raken bij het conflict. De rol die Nederland gaat spelen is nog onduidelijk; die beslissing ligt uiteindelijk bij de Tweede Kamer. Hoe kijkt de grootste partij van Nederland naar onze rol? Te gast is Jan Paternotte, fractievoorzitter van D66. Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Sven gaat met KLM-topvrouw Marjan Rintel in gesprek over de toekomst van haar luchtvaartmaatschappij, Schiphol en de wensen voor het nieuwe kabinet.  Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Hoe moet de Europese Unie reageren op het conflict in Iran? Veel critici vinden de Europese reactie tot nu toe te terughoudend en verwachten dat Nederland en andere Europese landen actiever optreden. VVD-Europarlementariër Bart Groothuis, vice-voorzitter van de Iran-commissie in het Europees Parlement, licht zijn standpunt toe bij Sven Kockelmann.  Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

In part two of this series, Dr. Justin Abbatemarco, Dr. Marjo S. van der Knaap, and Romy J. van Voorst discuss the patient management card and how patients should use it.  Show citation: and Clinical Management of Vanishing White Matter. Neurology. 2025;105(11):e214320. doi:10.1212/WNL.0000000000214320  Show transcript:  Dr. Justin Abbatemarco: Hello and welcome back. This is Justin Abbatemarco here with Romy J. van Voorst and Dr. Marjo S. van der Knaap. After discussing her article, Published Neurology Consensus Base Expert Recommendation for Diagnosis and Clinical Management of Vanishing White Matter Disease. Romy, I really want to talk with you about the patient management card. What inspired you to create that in this publication, and how should patients use that? Romy J. van Voorst:  So what the main motivation was of the study was actually a previous study that we did before. And in this study, we looked at the impact of any short matter on unaffected family members. And we found out that actually many family members encountered clinicians that were unfamiliar with its disease or disease-specific management. And during interviews, we saw that there was an urgent need for moral harmonization of care and also symptom management because families felt like they are left alone with just their child and no guidance on how to go further. And we wrote these recommendations to help families better understand the diagnostic and care process so they can also participate in informed decision-making. So they can understand what kind of preventive measures they can take and whether or not this interferes, for example, with quality of life goals. So there are a lot of different recommendations families can take home with. Dr. Justin Abbatemarco:  Marjo, anything else you want to add there? Dr. Marjo S. van der Knaap:  Yeah, I think the management card also helps because they have a physical card when they go to consultation or to emergency room that they can hand over. It's an official publication. It's developed by the Finishing WebMetter Expert Consortium in combination with other experts in combination with patient advocates and representatives. And so it's really a sort of a guidance that cannot be denied. So it has some authority to it. Dr. Justin Abbatemarco:  But I think it's a theme that applies to many neurological diseases, and addressing that. You do it really practically. And I agree, giving something more tangible for patients to present, especially to non-neurologists to help them give some guidance. It's an idea that we need to think about in clinic all the time on how we're interacting and supporting caregivers and when they're interfacing with the medical community at large. So I love what you guys have done here and to make us think about this more broadly. Thanks again for all your time and your work on this topic. Dr. Marjo S. van der Knaap:  Thank you for having us. 

In this episode of PEM Currents: The Pediatric Emergency Medicine Podcast, we take a structured, evidence-based approach to the acute treatment of migraine in children and adolescents. From confirming the diagnosis and screening for concerning features to optimizing outpatient therapy and executing a protocolized emergency department strategy, this episode walks through what works. We review the role of NSAIDs and triptans, clarify how IV fluids and ketorolac fit into care, and provide a stepwise framework for dopamine antagonists, valproate bridge therapy, DHE protocols, steroids, discharge planning, and admission decisions. Practical dosing, reassessment timing, and family-centered communication strategies are emphasized throughout. Learning Objectives Recognize the clinical features of pediatric migraine and distinguish it from secondary causes of headache. Implement a stepwise, evidence-based emergency department approach to acute pediatric migraine, including appropriate medication selection and timing of reassessment. Develop safe discharge and follow-up plans by defining treatment endpoints, minimizing medication overuse, and identifying patients who require referral or inpatient management. References 1. Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice Guideline Update Summary: Acute Treatment of Migraine in Children and Adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93(11):487-499. doi:10.1212/WNL.0000000000008095. 2. Patterson-Gentile C, Szperka CL. The Changing Landscape of Pediatric Migraine Therapy: A Review. JAMA Neurology. 2018;75(7):881-887. doi:10.1001/jamaneurol.2018.0046. 3. Bachur RG, Monuteaux MC, Neuman MI. A Comparison of Acute Treatment Regimens for Migraine in the Emergency Department. Pediatrics. 2015;135(2):232-238. doi:10.1542/peds.2014-2432. 4. Ashina M. Migraine. The New England Journal of Medicine. 2020;383(19):1866-1876. doi:10.1056/NEJMra1915327. 5. Richer L, Billinghurst L, Linsdell MA, et al. Drugs for the Acute Treatment of Migraine in Children and Adolescents. The Cochrane Database of Systematic Reviews. 2016;4:CD005220. doi:10.1002/14651858.CD005220.pub2. Transcript This transcript was generated using Descript automated transcription software and has been reviewed and edited for accuracy by the episode's author. Edits were limited to correcting names, titles, medical terminology, and transcription errors. The content reflects the original spoken audio and was not substantively altered. And today we're gonna talk about the acute treatment of migraine headache in children and adolescents. This is bread and butter for the PED, requires precise diagnosis and evidence-based treatment. We're gonna talk about making that diagnosis, red flags, outpatient and ED treatment, as well as some second-line agents, admission decisions, and a whole lot more. So migraine in children is defined by three criteria, and at least five attacks lasting two to 72 hours. So you gotta have at least two of the following: pulsating or throbbing quality, moderate to severe intensity, aggravation by routine activity, and a unilateral location. Although in children, it's often bilateral, plus at least one of nausea or vomiting and photophobia and/or phonophobia. In children headaches are frequently bilateral, bifrontal, bitemporal. The duration might be shorter than adults, especially in kids under second or third grade. And you may have to infer whether or not they have photophobia from their behavior. Like does the child close their eyes or wanna go into a dark room? In the emergency department, we're often diagnosing based on pattern recognition plus exclusion of dangerous secondary causes. Or even more often than that, the patient comes in and says, I've got a migraine. Before I move on to treatments, let's talk about some red flags where you might wanna pause and not just jump to migraine therapy. And the mnemonic SNOOP can be helpful here. And it stands for S for systemic symptoms such as fevers, myalgia, weight loss, or another S, secondary risk factors such as an immune deficiency, cancer, pregnancy, N for neurologic signs, papilledema, focal deficit, confusion, seizures. O onset sudden, or thunderclap. Migraines are often a little more gradual than that. The other O is older age, or technically younger age too, younger than five years or older than 50. Hopefully those patients are not coming into the pediatric emergency department. And then pattern changes, these new symptoms in a previously stable pattern. Don't ignore that. And precipitants, you know, is it worse with Valsalva, position change, or under significant exertion? If these signs are present, you'll probably wanna take a pause and just not throw migraine treatment at the patient. If they're stable, MRI is the preferred imaging modality, but a very sick patient, it'd be okay to get a head CT. If you've got a normal neurologic exam, there's no red flags. Again, you don't need routine imaging for migraine headaches. So let's talk about treatment. So hopefully patients have actually started to treat their headache before they arrive in the emergency department. If they haven't, it's a good idea to have some triage protocols in place. So ibuprofen, 7.5 to 10 milligrams per kilogram, 10 milligrams per kilogram is superior to placebo and it's superior to acetaminophen at two hours. So that's what we would use. Early treatment's critical. So ideally within the first hour of onset. So that's why triage protocols help. We'll give kids 10 mg per kg of ibuprofen and like 30 ounces of Gatorade. Blue is often the first Gatorade choice, though that's not an evidence-based statement. You can also use naproxen, but most of the studies are on ibuprofen. If NSAIDs fail, many adolescents and some older children will be prescribed triptans. The best evidence currently supports sumatriptan plus naproxen or zolmitriptan nasal spray. Rizatriptan is FDA approved down to age six. Adolescents respond to these agents better than younger children, and the route matters. The nasal formulations help when nausea is prominent. Families should be counseled to treat early, use weight-appropriate dosing, and avoid using acute medications more than 10 days per month. Often patients will have already taken an NSAID and a triptan before they get to the ED, and that's where we get into the treatment of refractory migraine. Now this is most of the patients that I will see, and before we push medications, let's briefly review ED treatment goals. You either want the patient headache free. Back to their baseline or mild descending pain. So a pain score of one to three. If you don't reach one of those endpoints and it's not agreed upon with the patient and their family, you've not completed treatments. You should do a reassessment within one hour after each intervention. And let's face it, if you're not reassessing within an hour and defining treatment goals, you're not practicing protocolized migraine care. So in the emergency department, many of you may be familiar with the migraine cocktail. So what is that? In general, it's a dopaminergic agent such as prochlorperazine or metoclopramide plus ketorolac, plus IV fluids. Let's take a look at all three of those components and see if you can guess which one is actually the one that can abort the migraine. So fluids are commonly given in pediatric migraine, but they alone do not treat it. They're helpful. Many patients have been throwing up or a bit dehydrated, but there are small randomized trials that show essentially no meaningful pain reduction in patients that get IV fluids alone. Well, what about ketorolac? Toradol, like that's the first thing you give to a kid with a kidney stone, right? It does help, but it's really adjunctive. So the main first-line agents for refractory or status migrainosus in the emergency department are the dopamine antagonists, and the first-line treatment for most patients is prochlorperazine or Compazine. The dose is 0.15 milligram per kilogram IV. The max is 10 milligrams. This is the backbone of ED migraine care. And why do they work? Well, migraines aren't just some random vascular headache. This is an inherited disorder with central pain pathways gone awry. Dopamine plays a large role in that pain, nausea, hypersensitivity, amplification of symptoms and more that, frankly, I won't get into this podcast because molecules hurt my head. The dopamine antagonists treat the headache, they reduce the nausea, and they just tamp down this process. Overall, the response rates approach 85%. Some studies have suggested that the response rate is about 77% at an hour and 90% at three hours. If you add the ketorolac and IV fluids, you get your response rate up to about 93 to 94%. These agents really do work well together. There have been randomized trials comparing IV prochlorperazine versus ketorolac. 85% of prochlorperazine patients achieved headache relief versus only 55% of ketorolac patients. So ketorolac helps, but really it's the prochlorperazine. Metoclopramide, or Reglan, is used in a lot of centers as well. There are some smaller studies in children and adolescents that show that prochlorperazine is more effective, but if kids have an adverse reaction, more on that in a moment, or they prefer metoclopramide because they've responded to it in the past, it's okay to go with it as well. Right. So what does it actually look like when you give the migraine cocktail to a patient? I think it's important to explain to patients and families what to expect, and if this is a teenager, I'm talking to them directly. I mean, they're getting the medication first and foremost. I tell them that the most effective way to treat their headache is with an IV. This often causes lots of angst, even in older teenagers. The medication just does not get to the brain as effectively and fast enough if you take it by mouth. Many patients who get the dopaminergic agents, so prochlorperazine, will invariably feel jittery or anxious or like they gotta move or like they got ants in their pants. I tell them to expect this so they're not surprised and worried when it happens. I tell them that once they start feeling that way, it means the medicine is probably working. They need to hit the nurse button and we're gonna get them up and have them take a walk. This fixes it for the majority of patients just getting up and moving. In adult centers, even with the initial administration of the prochlorperazine or as sort of a reflexive response to any of those symptoms, they just give a slug of IV Benadryl. There's some studies in adolescents especially that this may decrease the effectiveness of the IV agents you're giving in the first place, and it may also increase return rates to the ED. So I will use IV diphenhydramine if getting up and moving around isn't working, or if the distress is significant, or if the patient clearly indicates they've needed it in the past. So if after the migraine cocktail, the patient has met their pain goals and the reassessment is favorable, they can go home to outpatient follow-up. How about if the headache got better, but not all the way? It's usually when the initial migraine cocktail didn't achieve the pain endpoints fully, like it helped partially. If the dopamine blockade didn't do anything, valproate is unlikely to rescue the case. And so valproate works on GABA and it stabilizes some of these pain processes, but the dopaminergic agent needs to have done something first for valproate to work. Per the most common protocol, you give an initial dose of IV valproate, then you discharge the patient home on Depakote ER. So oral valproic acid under 10 years old or under 50 kilograms, 250 milligrams PO twice a day for two weeks, or older than 10 or greater than 50 kilos, 500 milligrams twice a day for two weeks. This is the extended release and it's most helpful if you give the first oral dose in the emergency department. So that's why it's very important to build this protocol in advance. If you don't have IV valproate, then don't just give the patient oral valproate, and definitely don't prescribe an oral course for discharge. All right, well, what about DHE? Dihydroergotamine for refractory or status migrainosus? Generally, this is only given at pediatric centers where you have neurology coverage. It's contraindicated if you've had another dose of DHE within 14 days, or you've had any triptan of any sort within 24 hours, and you must obtain a pregnancy test in adolescent females before giving it. The dosing for less than 30 kilograms is 0.5 milligram. At least 30 kilograms is one milligram. You give 50% of the dose over three minutes, then the remaining 50% over 30 minutes. If this is gonna work, the patients are gonna start feeling wretched at first. They're gonna get very nauseous and they're gonna vomit. They're gonna have flushing, and you'll see transient hypertension. Most of that resolves within the hour in most centers. If you're committing to DHE, you're kind of bringing the patient into the hospital anyway, though some facilities will have DHE done in the emergency department with close outpatient follow-up. Either way, it's really best practice to involve child neurology if you're giving DHE. Alright, well what about steroids? They give those in grownups too, right? Steroids really only have a role for recurrence prevention in children. So for kids that have a history of returning within 72 hours for rebound headache, you can give dexamethasone 0.6 milligram per kilogram IV dose, the max of 10 milligrams. You do not discharge them home on a steroid prescription or a Medrol dose pack or something else, and this can cut the recurrence risk down a bit. There's other therapies out there like magnesium and ketamine. There's just not enough evidence there. And the purpose of this episode is to discuss the therapies that have good evidence behind them and should be part of protocols across the country. Some patients are unfortunately not responsive to emergency department therapy and need admission. The main inpatient therapy is the DHE protocol. If they're not DHE eligible, they haven't tolerated it well or it's unavailable, admission's unlikely to help them unless they just need some IV fluids to help them get back up on their feet. You should consult neurology if the headache goals are not met after maximizing ED therapy for advice. And we should definitely avoid opioids. They don't treat patients with migraines. They increase recurrence risk. They increase revisit rates. Again, the dopamine antagonist prochlorperazine, it's superior for sustained relief when families ask about them, and fortunately they're asking about opioids far less. We use medications that treat the migraine pain pathways and signaling. We don't just wanna mask the pain. All right, so that's all I've got on the acute management of migraine headaches, especially in the emergency department. Remember that migraine care in the ED should be protocolized and evidence-based. IV fluids are supportive. Prochlorperazine is the first line, or you can use metoclopramide as well. Ketorolac is an adjunctive therapy. Valproate is next line. If you've gotta escalate, and DHE is specialized therapy, you can start in the ED, but most of these patients are getting admitted. Dexamethasone or steroids in children can reduce recurrence risk, but they're not really part of the acute management. You should definitely define the endpoints and structurally and systematically reassess patients at an hour. The goal is to get them feeling better to a defined endpoint and to restore function. There is evidence-based pediatric emergency migraine care. You should understand that, plus how to explain why these agents are being given and some of the side effects to patients and families. I find that that approach increases your likelihood of buy-in and success. Alright, so that's it for this episode on the Acute Management of Migraine Headaches in Children and Adolescents. I hope you found it helpful and I can pretty much guarantee that you're gonna see a patient with a migraine on your next shift. If you've got any feedback or comments, send them my way. If you like this episode, leave a review on your favorite podcast site. It helps more people find the show. Or recommend it to a colleague. If there's other topics that you'd like to hear, send them my way for the Pediatric Emergency Medicine podcast. This has been Brad Sobolewski. See you next time.    

Terwijl de raketten vliegen tussen de Golfstaten, Israël en Iran, blijft Europa hameren op de-escalatie. De meningen over deze reactie zijn verdeeld: die zou volgens sommigen te lauw zijn. Sven spreekt erover met Ruben Brekelmans.  Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Minister van Financiën Eelco Heinen, SGP-leider Chris Stoffer Minister van Langdurige Zorg, Jeugd en Sport Mirjam Sterk en politiek verslaggever Tessa van Viegen zijn te gast in Café Kockelmann. Café Kockelmann is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Na twee lange dagen debat over de nieuwe plannen van het kabinet, is de rust nog altijd niet teruggekeerd. De vakbonden weigeren vooralsnog in gesprek te gaan over de nieuwe AOW-maatregelen. Sven spreekt met FNV interim-voorzitter Dick Koerselman. Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

In part one of this two-part series, Dr. Justin Abbatemarco, Dr. Marjo S. van der Knaap, and Romy J. van Voorst discuss vanishing white matter disease, focusing on the clinical and MRI findings that would prompt the consideration of genetic testing.  Show citation: van Voorst RJ, Schoenmakers DH, Bonkowsky JL, et al. Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter. Neurology. 2025;105(11):e214320. doi:10.1212/WNL.0000000000214320  Show transcript:  Justin Abbatemarco: Hello and welcome. This is Justin Abbatemarco here with Romy J. van Voorst and Marjo S. van der Knaap. After discussing their article published in Neurology, Consensus-Based Expert Recommendation for Diagnosis and Clinical Management of Vanishing White Matter. They both work for Amsterdam University Medical Center in the Netherlands. And we're going to have a two-part episode dissecting maybe two elements of this paper. Marjo, maybe we could start here and just talking about what vanishing white matter disease is and what in the clinic and MRI findings would make us go towards a genetic testing. Dr. Marjo S. van der Knaap:  There are two things about vanishing white matter that matter most to families, and one is the stress sensitivity. So any type of physical stress, like fever, viral infection, anything may cause a rapid decline and you never know when it comes. And that brings me to the second item that's very difficult and painful for families. And that's the unpredictability. You never know when a disease is going to hit and then your child is going to go down. So you really need the support of neurologists who know about this disease and help you go through this situation. Dr. Justin Abbatemarco: Right. And this paper serves as a great resource for folks that if they have a patient in clinic like this, medications to avoid, how to manage those stress responses. And so it's a really helpful publication to have there. And then I think another message we talked a lot about on the podcast was the importance of genetic testing when patients aren't fitting a typical bucket and this specific disease has unique characteristics. I think the cystic appearance of the MRI, which you do a great job highlighting, would really lead us down that road. So I think it's all really helpful and it gives us some ways to start in clinic with patients and our caregivers. So thank you. Come back and join us for the second part of The Neurology Minute episode where we're going to talk about the patient management. 

Dag twee van het debat over de regeringsverklaring begint onstuimig met een felle discussie over de AOW. De vakbonden weigeren in gesprek te gaan met het kabinet zolang de aangekondigde maatregelen niet van tafel zijn. Oud-informateur en voormalig PvdA-fractievoorzitter Jacques Wallage bespreekt het met Sven. Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Premier Jetten trapte vandaag het debat over de regeringsverklaring af. De komende twee dagen debatteert de Kamer over de nieuwe plannen van het kersverse kabinet. Hoe bereidt een nieuwe premier zich hierop voor? Sven bespreekt het met voormalig VVD-campagnestrateeg Bas Erlings. Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

De oorlog in Oekraïne gaat vandaag haar vijfde jaar in. Hoe blikt Commandant der Strijdkrachten Onno Eichelsheim terug op vier jaar oorlog? En hoe zal Nederland zich de komende tijd, met een nieuwe minister, inzetten voor de veiligheid van Oekraïne en Europa? Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Onze analist van dienst stond al met zijn neus bij de etalage voor een paar aandeeltjes Klarna, toen deze op $30 noteerde. Als een kindje dat pruimen zag hangen, o, als appelen zo groot! Maar wat kan hij in zijn handjes wrijven, want de bodem was voor Klarna nog lang niet in zicht. Na de beursgang in september verloor de Zweedse fintech 70% van haar marktwaarde. Terecht, of is Klarna de kans van de eeuw? En Trump stort beleggers wereldwijd weer in de onzekerheid met zijn heffingenheisa. Goed nieuws voor Azië, waar de nieuwe heffingen lager uitpakken dan de vorige. In het VK zullen ze daarentegen minder staan te springen. Wat is er dit weekend nou precies gebeurd, en wat betekent dat voor jou? Ook daar is genoeg om uit te pakken. Verder in deze show: Box-3 voer voor hoofdredactie Washington Post Netflix bestuurslid moet ONMIDDELIJK ontslagen worden van Trump, terwijl ze middenin de overnamestrijd rond Warner Bros zitten McDonalds is het nieuwe goud Waarom de Zuid-Koreanen dol zijn op hefboompjes VEB wil dat de AFM onderzoek gaat doen naar handel met voorkennis in aandelen van InPost Te gast: Justin Blekemolen van online broker Lynx BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij BNR Zakendoen en de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

Nederland heeft weer een missionair kabinet. Alle ministers zijn beëdigd en de bordesfoto's zijn gemaakt. Ank Bijleveld maakt dit mee als minister van Defensie in Rutte III. Tegenwoordig is ze voorzitter van het instituut dat zich buigt over lintjes en op de achtergrond betrokken bij het scouten van politiek talent bij het CDA.  Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Onze analist van dienst stond al met zijn neus bij de etalage voor een paar aandeeltjes Klarna, toen deze op $30 noteerde. Als een kindje dat pruimen zag hangen, o, als appelen zo groot! Maar wat kan hij in zijn handjes wrijven, want de bodem was voor Klarna nog lang niet in zicht. Na de beursgang in september verloor de Zweedse fintech 70% van haar marktwaarde. Terecht, of is Klarna de kans van de eeuw? En Trump stort beleggers wereldwijd weer in de onzekerheid met zijn heffingenheisa. Goed nieuws voor Azië, waar de nieuwe heffingen lager uitpakken dan de vorige. In het VK zullen ze daarentegen minder staan te springen. Wat is er dit weekend nou precies gebeurd, en wat betekent dat voor jou? Ook daar is genoeg om uit te pakken. Verder in deze show: Box-3 voer voor hoofdredactie Washington Post Netflix bestuurslid moet ONMIDDELIJK ontslagen worden van Trump, terwijl ze middenin de overnamestrijd rond Warner Bros zitten McDonalds is het nieuwe goud Waarom de Zuid-Koreanen dol zijn op hefboompjes VEB wil dat de AFM onderzoek gaat doen naar handel met voorkennis in aandelen van InPost Te gast: Justin Blekemolen van online broker Lynx BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij BNR Zakendoen en de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

Een paar dagen voordat Dick Schoof de sleutels van het Catshuis overhandigt aan zijn opvolger, blikt hij met presentator Sven Kockelmann terug op zijn premierschap.  Café Kockelmann is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Dr. Alex Menze and Dr. Divyanshu Dubey discuss the clinical insights into autoimmune nodopathies, particularly focusing on CASPR1 and CASPR1/CNTN1-complex-IgG.  Show citation:  Paramasivan NK, Basal E, LaFrance-Corey RG, et al. Clinical Insights Into CASPR1 and CASPR1/Contactin-1 Complex Autoimmune Nodopathies. Neurology. 2026;106(5):e214403. doi:10.1212/WNL.0000000000214403 Show transcript:  Dr. Alexander Menze: Hi, this is Alexander Menze. I just finished interviewing Divyanshu Dubey for the Neurology podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your paper. Dr. Divyanshu Dubey: Our paper talks about a rare form of autoimmune neuropathy associated with antibodies, CASPR1, as well as CASPR1/Contactin-1 complex IgG. These patients present with similar to CIDP, IDP, but tend to have more rapid progression, often a lot of sensory features preceding motor deficits including sensory ataxia in the contact and CASPR complex cases and presence of neuropathic pain in some of the CASPR1 cases. These patients, similar to other neuropathies are refractory to IVIg, but respond relatively well to rituximab.  Dr. Alexander Menze: Thank you. Be sure to download this week's podcast to hear our full interview.  

Komende maandag staat het kersverse nieuwe kabinet-Jetten op het bordes. Al langer pleit toponderhandelaar Maarten van Rossum voor een minderheidskabinet. Maar hoe werkt dat in de praktijk en hoe haal je meerderheden?  Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Dr. Halley Alexander and Dr. Alissa M. D'Gama discuss genetic testing for infantile epilepsies.  Show citation:  Nguyen JNH, Lachgar-Ruiz M, Higginbotham EJ, et al. Diagnostic Yield of Comprehensive Reanalysis After Nondiagnostic Short-Read Genome Sequencing in Infants With Unexplained Epilepsy. Neurology. 2026;106(6):e214645. doi:10.1212/WNL.0000000000214645  Show transcript:  Dr. Halley Alexander:  Hi, this is Halley Alexander with today's Neurology Minute, and I'm here with Dr. Alissa D'Gama from Boston Children's Hospital and Harvard Medical School, and we just finished recording a full-length podcast about some exciting new work in genetic testing for infantile onset epilepsies. Alissa, can you tell us what you found briefly and why it's important for neurology care? Dr. Alissa D'Gama:  Infantile epilepsies are relatively common, and they're associated with substantial burden of disease, and we know that identifying underlying genetic causes can impact clinical care. It's important for emerging precision therapies. But even after genome sequencing, which is the most comprehensive clinical genetic testing currently available, most infants remain genetically unsolved. And so what we did was take that genome sequencing data and reanalyze it for a cohort of infants who had unexplained non-acquired epilepsy and non-diagnostic genome sequencing, and in about 5% of cases, our reanalysis was able to identify a genetic diagnosis, and all of these diagnoses had impact on clinical care for their infants and their families. In some cases, we could incorporate new information, either new clinical information about the patient or new scientific methods or information about disease associations, and in other cases, we were able to incorporate new analysis methods to identify variants. And so our findings suggest that implementing reanalysis for infants or any individual with epilepsy within a year or two of non-diagnostic testing may be useful. Dr. Halley Alexander:  Thank you so much, and you can find a lot more details by listening to the full-length podcast, which is available now on the Neurology podcast, and you can find the full article in the March 10th issue of Neurology or online at neurology.org. As always, thanks for tuning in for today's Neurology Minute. 

Hij was slechts zes maanden minister van Onderwijs, Cultuur en Wetenschap, maar turbulent was het zeker. In gesprek met Sven blikt Gouke Moes terug op zijn periode als BBB-bewindspersoon en bespreekt hij de staat van het onderwijs.  Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Het Franse platform Intelligence Online meldt dat Nederlandse ex-F-16-piloten deel uitmaken van een Oekraïense eenheid die het luchtruim van Kiev bewaakt. Hoe realistisch is dat verhaal? Sven bespreekt het met oud-Commandant der Strijdkrachten  Dick Berlijn. Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Hij is de verpersoonlijking van het poldermodel. Meermalen uitgeroepen tot de machtigste persoon van het land, zat hij aan álle overlegtafels die ertoe doen. Alexander Rinnooy Kan schreef een boek over zijn levenservaringen en inzichten in een veranderende wereld. Wieger Hemmer gaat met hem in gesprek.  Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief 

Het cv-gedoe rondom Nathalie van Berkel kost het Kamerlid haar kansen om staatssecretaris te worden van Financiën. De D66'er had op haar cv meerdere opleidingen staan die ze of niet had gevolgd of niet had afgemaakt, bleek uit een analyse van De Volkskrant. "Als politici een loopje nemen met de waarheid, moeten we dat belangrijk vinden", zegt hoofdredacteur Pieter Klok, die benadrukt dat Van Berkel zichzelf naar voren had geschoven voor een profiel in de krant. "Op het moment dat je zo'n vertrouwensbreuk hebt veroorzaakt met je achterban, vraag ik me af hoe houdbaar je bent als Kamerlid", reageert Elif Isitman, programmamaker bij WNL. 

Dr. Greg Cooper and Dr. David G. Coughlin discuss the role of αSyn-SAAs in diagnosing DBL and their relationship with Alzheimer's disease biomarkers.  Show citation: Coughlin DG, Jain L, Khrestian M, et al. CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression. Neurology. 2025;105(12):e214346. doi:10.1212/WNL.0000000000214346 Show transcript:  Dr. Greg Cooper: Hi, this is Dr. Greg Cooper. I just finished interviewing Dr. David Coughlin for this week's Neurology Podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your paper. Dr. David Coughlin: The main points of this paper in my mind is that α-Synuclein seed amplification assays from cerebrospinal fluid samples is useful in confirming the presence of synuclein pathology in people with clinically suspected dementia with Lewy bodies. But also that, for people who have synuclein positivity, that the presence of Alzheimer's disease mixed pathology is associated with a worse cognitive progression over time. Dr. Greg Cooper: Thank you Dr. Coughlin, for that summary and for all of your work on this topic. Please check out this week's podcast to hear the full interview and read the full article published in Neurology, CSF α-Synuclein Seed Amplification Assays and Alzheimer's Disease Biomarkers in Dementia with Lewy Bodies. Thank you.

Dr. Tesha Monteith and Dr. Michael Eller discuss the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke.  Show citation: Eller MT, Schwarzová K, Gufler L, et al. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. Neurology. 2025;105(2):e213852. doi:10.1212/WNL.0000000000213852  Show transcript:  Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Michael Eller from the Department of Neurology Medical University of Innsbruck, Austria on the neurology podcast on his paper, CGRP Targeted Migraine Therapies in Patients with Vascular Risk Factors or Stroke: A Review. Hi, Michael. Dr. Michael Eller: Hello. Dr. Tesha Monteith: Why don't you summarize your general approach to use of CGRP targeted therapies in patients that might be at risk for vascular events when considering safety? Dr. Michael Eller: Yeah. About acute vascular events, we should stop CGLP targeted drugs immediately. When we come to post-stroke, we should reassess the necessity of these targeted treatments after recovery. We suggest a minimum of three months pause after ischemic stroke to allow early recovery and remodeling, and then restart only after individualized benefit risk review. In high-risk primary prevention, so no stroke yet, but elevated risk, if the patients are 65 years or older with established cardiovascular disease, we should prefer traditional preventives. And if CGLP targeted therapy is essential, we should consider Gepants cautiously due to their shorter half lives. We should avoid CGLP targeted treatments in small vessel disease, distal stenosis, Raynaud's phenomenon, and uncontrolled hypertension. For acute migraine treatment, we can consider gepants or ditans as alternatives to triptans and NSAIDs in relevant stroke risk or post-stroke patients, individualized to comorbidities. Dr. Tesha Monteith: Great. And we should say that the label updates include hypertension and Raynaud's phenomenon as potential vascular complications. Otherwise, these are more theoretical risks based on what we know about CGRP. Dr. Michael Eller: Yes, I totally agree because large studies did not show any elevated cardiovascular risk signals. And for post-marketing databases, we did not see any elevated cardiovascular risk so far. However, in pre-clinical settings, studies showed large infarct size in pretreated mice. Dr. Tesha Monteith: Great. Well, thank you again for doing this work. It was a phenomenal read and congratulations. Dr. Michael Eller: Thank you. Dr. Tesha Monteith: This is Tesha Monteith. Thank you for listening to the Neurology Minute.

Welcome back to the Richmond Chi Alpha podcast!We're continuing in our series called “Highly Questionable” where we talk about lives that provoke curiosity, invite deeper questions, and transform the world around us.This week, I talk about how we're called to faith in action, and how habits and rhythms in our lives can help us to live aligned with the reality of God's Kingdom.Let's listen together!This was recorded from a WNL on 1/21/26.

Estima-se que em torno de 15% da população mundial sofra de enxaqueca, com maior prevalência nas mulheres - e muitos sintomas, tais como aura, além de hipersensibilidade à luz, ao som e ao cheiro... Afinal, o que a ciência tem a dizer sobre o tema?Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.>> OUÇA (60min 43s)Convidado: Dr. Fabiano Moulin de MoraesMédico neurologista pela Escola Paulista de Medicina da UNIFESP, onde é preceptor da residência em Neurologia. Membro titular da Academia Brasileira de Neurologia, Professor da Casa do Saber e Especialista em neurologia da cognição e do comportamento. Participou do Naruhodo Entrevista 48.* Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*APOIO: INSIDERIlustríssima ouvinte, ilustríssimo ouvinte do Naruhodo, janeiro é tempo de recomeços - e o recomeço mais importante é o momento em que acordamos, todos os dias.Afinal, a escolha da manhã muda tudo:- Vestir a roupa de treino assim que acorda — mesmo treinando só à tarde — aumenta a chance de cumprir a meta.- Colocar uma peça inteligente para trabalhar ou criar conteúdo te coloca instantaneamente em modo produtivo e confiante.- Mesmo para ficar em casa, trocar o pijama por um look confortável e bonito muda o humor, a energia e a presença.Ou seja: a Insider entra no seu ritual matinal e acompanha sua rotina com naturalidade.Então use o endereço a seguir pra já ter o cupom NARUHODO aplicado ao seu carrinho de compras: são 10% de desconto, ou 15% de desconto caso seja sua primeira compra.>>> creators.insiderstore.com.br/NARUHODOOu clique no link que está na descrição deste episódio.E bons recomeços pra você!INSIDER: inteligência em cada escolha.#InsiderStore*REFERÊNCIASMigraine Triggers: An Overview of the Pharmacology, Biochemistry, Atmospherics, and Their Effects on Neural Networkshttps://pmc.ncbi.nlm.nih.gov/articles/PMC8088284/Migraine and cognitive dysfunction: a narrative reviewhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11657937/Structural and Functional Brain Changes in Migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC8119592/Migraine: Multiple Processes, Complex Pathophysiologyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4412887/Migraine management: Non-pharmacological points for patients and health care professionalshttps://www.degruyterbrill.com/document/doi/10.1515/med-2022-0598/htmlIs there a causal relationship between stress and migraine? Current evidence and implications for managementhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8685490/The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Regionhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11751287/Practical issues in the management of sleep, anxiety, and mood disorders in primary headacheshttps://pmc.ncbi.nlm.nih.gov/articles/PMC12221693/Differentiating Visual Symptoms in Retinal Migraine and Migraine With Aura: A Systematic Review of Shared Features, Distinctions, and Clinical Implicationshttps://pmc.ncbi.nlm.nih.gov/articles/PMC12380025/Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategieshttps://pmc.ncbi.nlm.nih.gov/articles/PMC11940401/Migrainehttps://www.nejm.org/doi/10.1056/NEJMra1915327Pratice guideline update summary: Acute treatment of migraine in children and adolescentshttps://www.neurology.org/doi/10.1212/WNL.0000000000008095Migraine aura as an artistic resource https://nah.sen.es/vmfiles/vol13/NAHV13N22025102_115EN.pdfMigraine aura as artistic inspiration.https://pmc.ncbi.nlm.nih.gov/articles/PMC1838881/Migraine as a source of artistic inspirationhttps://neuro.org.br/pdfs/RBN-59/RBN-594-DEZEMBRO/RBN-594-DEZEMBRO.pdf#page=44Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysishttps://pmc.ncbi.nlm.nih.gov/articles/PMC12534955/Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysishttps://pmc.ncbi.nlm.nih.gov/articles/PMC11409395/The impacts of migraine on functioning: Results from two qualitative studies of people living with migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC10922598/Exploring the Hereditary Nature of Migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC8075356/Transient receptor potential melastatin 8 (TRPM8) is required for nitroglycerin and calcitonin gene-related peptide induced migraine-like pain behaviors in micehttps://pmc.ncbi.nlm.nih.gov/articles/PMC9519811/Association between weather conditions and migraine: a systematic review and meta-analysishttps://link.springer.com/article/10.1007/s00415-025-13078-0Evaluation of Green Light Exposure on Headache Frequency and Quality of Life in Migraine Patients: A Preliminary One-way Cross-over Clinical Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8034831/CGRP — The Next Frontier for Migrainehttps://www.nvvg.nl/files/3306/CGRP%20—%20The%20Next%20Frontier%20for%20Migraine.pdfDigital Media Use in Adolescents with Migraine: A Topical Reviewhttps://link.springer.com/article/10.1007/s11916-025-01444-6Placebo Response in Acute and Prophylactic Treatment of Migrainehttps://www.neurologic.theclinics.com/article/S0733-8619(25)00068-4/abstractCalcitonin Gene–Related Peptide Inhibitors and Cardiovascular Events in Patients With Migrainehttps://www.neurology.org/doi/abs/10.1212/WNL.0000000000214479?casa_token=WccpvEByt0MAAAAA:LKbxQClihNe2WsrHRKBmteHftcUECeozPKYcnSQPjsBA0hlEvKExc2DvBgn-J5WwWyudd3QV1nluWwInsights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesishttps://journals.sagepub.com/doi/10.1177/03331024241287224Elucidating the susceptibility genes between insomnia and migraine by integrating genetic data and transcriptomeshttps://link.springer.com/article/10.1186/s10194-025-02249-zThe experience of neck pain in people with migraine: A qualitative studyhttps://www.sciencedirect.com/science/article/pii/S1413355525003922?casa_token=9ct7RuiXWIgAAAAA:Sxlqh2wKO3-2l4ig9hzuXb92eJtttlM1Mdd3EId-5BfNQ2J8kpTn2iCd3tr6a0l58kyqDTDR7wThe impact of pain on memory: a study in chronic low back pain and migraine patients https://academic.oup.com/braincomms/article/8/1/fcaf486/8376909Migraine as a dynamic continuum during the life coursehttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00441-7/abstractNaruhodo #447 - O que é AVC e como evitá-lo? #TodosPeloPirullahttps://www.youtube.com/watch?v=vRu9cet1TWMNaruhodo #236 - Por que temos dor de cabeça?https://www.youtube.com/watch?v=q8FtXVlSz1INaruhodo #345 - Por que às vezes sentimos as dores dos outros?https://www.youtube.com/watch?v=mKdMBCqy6XANaruhodo #145 - Por que a cabeça dói quando tomamos gelado?https://www.youtube.com/watch?v=qjq2Ds6YB-cNaruhodo #165 - Quando tomo antidepressivos continuo sendo eu mesmo?https://www.youtube.com/watch?v=dWyfUyHUiA4Naruhodo #62 - Existem doenças psicossomáticas?https://www.youtube.com/watch?v=etuFYdCAKe4Naruhodo #288 - Por que existe a menopausa?https://www.youtube.com/watch?v=3Ewwdi2guWgNaruhodo #339 - Por que as coisas parecem girar quando estamos bêbados?https://www.youtube.com/watch?v=YmK1Yq0mwW8Naruhodo #398 - Jejum intermitente funciona?https://www.youtube.com/watch?v=lTkWGFFkOLo*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser. O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo

Dr. Elizabeth Coon and Prof. Franziska Hopfner discuss the frequency and disease trajectory of MSA patients who do not experience dysautonomia, in comparison to those with autonomic involvement. Show citation:  Wilkens I, Bebermeier S, Heine J, et al. Multiple System Atrophy Without Dysautonomia: An Autopsy-Confirmed Study. Neurology. 2025;105(11):e214316. doi:10.1212/WNL.0000000000214316 Show transcript:  Dr. Elizabeth Coon: Welcome to the Neurology Minute. I'm Elizabeth Coon, and I'm delighted to welcome Professor Hopfner, who will give us a summary of her recently published paper in Neurology, "Multiple System Atrophy Without Dysautonomia and Autopsy Confirmed Study." Welcome, Professor Hopfner. Please tell us about this study and the key findings. Prof. Franziska Hopfner: So this work reframes how we think about MSA. So, autonomic failure is common but not universal and its absence does not rule out the diagnosis of MSA. So recognizing motor only in multiple system atrophy expands our diagnostic accuracy, improves patients consulting and broadens inclusions in future therapeutic trials. Dr. Elizabeth Coon: Excellent. Thank you. And thank you for listening to this Neurology Minute.

Dr. Derek Stitt and Drs. Joseph Safdieh and Matthew S. Robbins discuss subspecialization's impact on patient care, why preserving a core neurologist identity matters, and how training can reinforce it. Show citation: Safdieh JE, Robbins MS. Opinion & Special Articles: The Core Identity of the Neurologist. Neurology. 2025;105(9):e214265. doi:10.1212/WNL.0000000000214265 

Dr. Shuvro Roy and Dr. Rosa Cortese discuss new ways to improve MS and MOGAD diagnosis, including how AI and imaging could enhance accuracy and influence future care. Show citations: Cortese R, Sforazzini F, Gentile G, et al. Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated Disease. Neurology. 2025;105(6):e214075. doi:10.1212/WNL.0000000000214075 

Drs. Mahinda Yogarajah, Benjamin Tolchin, and Jon Stone discuss recommendations for clinicians, patients, and other stakeholders on the management of functional seizures.  Show citation: Tolchin B, Goldstein LH, Reuber M, et al. Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee. Neurology. 2026;106(1):e214466. doi:10.1212/WNL.0000000000214466  Show transcript:  Dr. Mahinda Yogarajah: Welcome to this edition of Neurology Minute. I'm your host for this. My name's Mahinda Yogarajah. I've just finished interviewing Dr. Ben Tolchin and Jon Stone for this week's Neurology® Podcast. For today's Neurology Minute, I'm hoping Ben can tell us the main points of the podcast and the paper discussed in that podcast. Dr. Ben Tolchin: We discussed the AAN guideline on the Management of Functional Seizures. This is the first American Academy of Neurology evidence-based guideline on functional neurologic disorder. It includes a systematic review of the randomized controlled trials relating to the treatment of this disorder, which found that psychological interventions are possibly effective in improving the chance of achieving freedom from functional seizures, in reducing the frequency of functional seizures, in improving quality of life, and in improving anxiety. In addition to the systematic review, there are clinical recommendations based on the systematic review and on related evidence. The recommendations deal with all stages of the diagnosis, management, and treatment of functional seizures and are particularly relevant to neurologists caring for patients with functional seizures. In addition, there are recommendations for future research relating to the diagnosis and management of functional seizures. Dr. Mahinda Yogarajah: Thank you, Ben. For more information, I'd recommend go to the main podcast or go and have a read of the article that's been published in Neurology® on the Management of Functional Seizures Practice Guidelines.

Drs. Greg Cooper, Natalia Rost, and Behnam Sabayan discuss preventive neurology and the need for neurologists to move beyond diagnosis and treatment toward proactive strategies for brain health.  Show citation: Sabayan B, Boden-Albala B, Rost NS. An Ounce of Prevention: The Growing Need for Preventive Neurologists. Neurology. 2025;105(1):e213785. doi:10.1212/WNL.0000000000213785 Show transcript:  Dr. Greg Cooper: Hi, this is Greg Cooper. I just finished interviewing Behnam Sabayan and Natalia Rost for this week's Neurology® Podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your paper, An Ounce of Prevention, the Growing Need for Preventative Neurologist. Dr. Behnam Sabayan: We are living in a very exciting time for the field of neurology where we are not just getting very good at diagnosis and treatment of neurological condition, but also we are stepping one step back, and that means that we will find the root causes of neurological conditions. We would act as preventive specialists and we would decrease the burden of neurological conditions, not just at the individual level, but also at the population level. And this paper calls for thinking about playing roles at different levels and stages from our offices and our rounds all the way to the community to be brain health advocates and helping other fields and disciplines to reduce the burden of neurological conditions. Dr. Greg Cooper: Well, thank you for that summary and for all of your work on this topic. Please check out this week's podcast to hear the full interview or read the full article published in Neurology®, An Ounce of Prevention: The Growing Need for Preventative Neurologists. Thank you.

In part five of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss treatment options.  Show citation:  Gilmour, G.S., Nielsen, G., Teodoro, T. et al. Management of functional neurological disorder. J Neurol 267, 2164–2172 (2020). https://doi.org/10.1007/s00415-020-09772-w  Gilmour GS, Langer LK, Bhatt H, MacGillivray L, Lidstone SC. Factors Influencing Triage to Rehabilitation in Functional Movement Disorder. Mov Disord Clin Pract. 2024;11(5):515-525. doi:10.1002/mdc3.14007  Stone J, Carson A. Multidisciplinary Treatment for Functional Movement Disorder. Continuum (Minneap Minn). 2025;31(4):1182-1196. doi:10.1212/cont.0000000000001606 Tolchin B, Goldstein LH, Reuber M, et al. Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee. Neurology. 2026;106(1):e214466. doi:10.1212/WNL.0000000000214466  Show transcript:  Dr. Jon Stone: Hello, this is Jon Stone with the Neurology Minute. Gabriela Gilmour and I are back to continue with part five of our seven-part series on FND. Today we'll be discussing treatment. Gabriela, talk us through what the rehabilitation or therapy approaches exist for FND now. Dr. Gabriela Gilmour: I would start actually even before jumping into rehabilitation and therapy to again emphasize something that we talked about in the last episode, which is that rehabilitation very much starts at our first visits with our patients when we examine for positive signs and show these to our patients and explain what they mean. So education about FND is really a fundamental treatment step, and I think we as neurologists have so much to offer to our patients in these visits. Next, when we're thinking about rehabilitation for FND, this often includes some combination of physical rehabilitation and psychological therapy and really should be individualized to each patient. So multidisciplinary or integrated therapy approaches are the gold standard and treatment strategies with these are really guided by our evolving understanding of the mechanisms of FND. So for example, this means using strategies like distraction, motor visualization, relaxation and mindfulness to target that underlying mechanism of FND. And then we use psychological therapies to also address perpetuating factors. So as we have discussed in this series, patients often experience many symptoms. So we also want to think about those other symptoms in our treatment plan, whether that be chronic pain or sleep disturbance or treating comorbid psychiatric or neurological illness. When we think about the subtypes of FND, there is some research into specific strategies for each. So psychotherapy, in particular, cognitive behavioral therapy is the focus for functional dissociative seizures with strategies aimed at attack prevention. Whereas for functional movement disorder, motor retraining physiotherapy has the most evidence. One big thing that I want to emphasize though is that rehabilitation for FND really relies on patient self-management and patient engagement. So I often explain to my patients that I can't retrain their brain, but I can help support them in this process and doing this for themselves. Dr. Jon Stone: So when you meet a patient with FND, how do you decide whether therapy is going to be helpful for them? I think people often have a tendency to say, "Oh, it's FND right off you go to psychotherapy or physiotherapy," but is that always the right option? How should we try and help our patients to decide if it's the right time for them to do these treatments? Dr. Gabriela Gilmour: Yeah, I think that that's something that's really maybe not unique, but something that's really important to FND and to treatment planning and FND. When we're supporting our patients as they embark on a treatment pathway, we really want to set them up for success. And so this really does rely on a robust triage process. So unlike other neurological conditions where you have X disease, therefore, why is the treatment? For FND, we've got a host of different types of treatments, and we want to individualize that and we want to time it right. Fundamentally, we really want to select the right treatment for our patients, and that relies on us understanding what symptoms are most bothersome to our patients, and we want to then provide that treatment at the right time. And I think right time is really what I would emphasize as being so, so important. So this means that patients are ready for active participation and rehabilitation, they're enthusiastically opted in. They think that treatment's going to help, and there aren't major barriers that are going to impact their ability to participate fully, so things like severe pain that could get in the way. And this is a conversation that I have really openly with my patients, and I really try to let them guide the timing. They will let me know, "Hey, I'm a teacher, and I'm in school right now. Now is not the right time for me to embark on this, but what about in June or July?" And then we revisit and regroup at that time. So really I do let my patients guide this process, but I would say that there are a subset of patients that don't need these more advanced rehabilitation type programs. Maybe are spontaneously improved or are able to implement some of their own self-management strategies on their own and have a significant improvement in symptoms already. Dr. Jon Stone: We need to make it easy for our patients to tell us when it's not the right time, but also, there's no one-size-fits-all, basically. Dr. Gabriela Gilmour: Absolutely. Dr. Jon Stone: So we'll be back for more Neurology Minute to continue our discussion on FND. We'll be talking about prognosis. Thanks for listening.

Dr. Zohaib Siddiqi talks with Dr. Catarina Bernardes about a case involving a 35-year-old woman presenting with personality changes and gait impairment.  Show citation:  Bernardes C, Lemos JM, Santo GC. Clinical Reasoning: A 35-Year-Old Woman With Personality Change and Gait Impairment. Neurology. 2025;104(2):e210252. doi:10.1212/WNL.0000000000210252  Show transcript:  Dr. Zohaib Siddiqi: Hi, everyone. My name is Zohaib Siddiqi and I'm a fifth-year neurology resident and a part of the Neurology® Resident and Fellow Section Editorial Board. I just finished interviewing Catarina Bernardes about her article, Clinical Reasoning: A 35-year-old Woman with Personality Change and Gait Impairment. Catarina, can you tell us the main points of the article? Dr. Catarina Bernardes: So in this article, we discussed the case of a 35-year-old woman who presented with a three-year history of walking difficulties. On examination, she had signs of a frontal temporal dysfunction, a dorsal lateral myelopathy, optic atrophy, and pes cavus. Her brain and spinal cord MRI was completely normal, but her son's brain MRI was being studied for spastic paraparesis showed signs of hypomyelination involving the subcortical U fibers. Given the suggestive inheritance pattern, we considered an X-linked leukoencephalopathy and central nervous system hypomyelination points to Pelizaeus-Merzbacher disease. Important learning points. When differentiating leukoencephalopathies, remember that hypomyelinating disorders often have less pronounced hypointensity on T2 and hypointensity on T1, and in demyelinating disorders, there is very prominent hyperintensity on T2 and hypointensity on T1. Also, Pelizaeus-Merzbacher is a hypomyelinating disorder affecting the subcortical U fibers, while X-linked adrenoleukodystrophy presents a demyelinating pattern sparing the subcortical U fibers and involving mainly the parietooccipital regions. Dr. Zohaib Siddiqi: Thanks so much for that summary, Catarina. A lot of learning points there. For those of you who want to learn more about the case, you can listen to the full-length podcast available now on all streaming platforms and find the article titled, Clinical Reasoning: A 35-year-old Woman with Personality Change and Gait Impairment on the Neurology® Resident Fellow Website. Thanks so much for joining today, and see you next time. 

In the final episode of our five-part series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses bedside testing for PPA.  Show citations:  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

In the final episode of our five-part series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses bedside testing for PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

In the fourth installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses semantic variant PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

In the third installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses nonfluent/agrammatic PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

Dr. Alex Menze and Professor Hakan Cetin discuss the need to reevaluate the approach to diagnosing and treating seronegative myasthenia gravis.  Show citations:  Krenn M, Wagner M, Schuller H, et al. Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing. Neurology. 2025;105(8):e214177. doi:10.1212/WNL.0000000000214177 

In the second installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses logopenic PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

In the first part of this series, Dr. Rogan Magee provides an introduction to primary progressive aphasia (PPA) and explains its three subtypes.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

Dr. Dan Ackerman and Dr. Isabel Hostettler discuss the diagnosis, risk factors, and prognosis of RCVS, highlighting the need to recognize symptoms and distinguish it from other causes of subarachnoid hemorrhage.  Show reference:  Hostettler IC, Ponciano A, Wilson D, et al. Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis. Neurology. 2025;105(5):e213984. doi:10.1212/WNL.0000000000213984 

In part two of this series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss gender disparities in the treatment of multiple sclerosis.  Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated.  Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-457 Overview: Many patients turn to low- and no-calorie sweeteners to help with weight loss and lower diabetes risk, but do these alternatives actually deliver? In this episode, we review common artificial sweeteners and explore evidence on hunger, cardiovascular, diabetes, and dementia risks to understand how sugar substitutes can impact long-term health outcomes in your patients. Episode resource links: fMRI Data: Nat Metab 7, 574–585 (2025). https://doi.org/10.1038/s42255-025-01227-8 Adverse effects: Adv Nutr. 2023 Jul;14(4):710-717. doi: 10.1016/j.advnut.2023.05.010 Dementia Data: Neurology® 2025;105:e214023. doi:10.1212/WNL.0000000000214023 Stevia: Obes Rev. 2025 Jun;26(6):e13902. doi: 10.1111/obr.13902 High Fructose Corn Syrup:  Nutrition Reviews. 2021;79(2):209-226.  doi:10.1093/nutrit/nuaa077 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

The November 2025 Recall revisits four insightful episodes centered on muscle and neuromuscular diseases. Kicking off the episode is a two-part series on myositis, where Dr. Stacey Clardy speaks with Dr. Andrew Mammen. The episode continues with an interview featuring Dr. Eric Voorn, who discusses the effectiveness of combining personalized, home-based aerobic exercise with coaching to improve physical fitness in individuals with neuromuscular diseases. The episode wraps up with Dr. Elia Sechi discussing the critical role of interpreting lab test results, understanding assay performance, and recognizing the real-world impact of false positives in myasthenia gravis diagnostics.  Podcast links: Updates on All Things Myositis – Part 1  Updates on  All Things Myositis - Part 2 Efficacy of Aerobic Exercise and Coaching on Physical Fitness in Neuromuscular Disease  False Positivity of Acetylcholine Receptor Autoantibodies in Clinical Practice Article links: Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice Show citations:  Oorschot S, Brehm MA, van Groenestijn AC, et al. Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases: A Randomized Clinical Trial. Neurology. 2025;105(1):e213781. doi:10.1212/WNL.0000000000213781 Zara P, Chessa P, Deiana GA, et al. Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice. Neurology. 2025;104(9):e213498. doi:10.1212/WNL.0000000000213498 Disclosures can be found at Neurology.org.